全文获取类型
收费全文 | 100108篇 |
免费 | 28988篇 |
国内免费 | 1072篇 |
专业分类
耳鼻咽喉 | 2426篇 |
儿科学 | 2770篇 |
妇产科学 | 2423篇 |
基础医学 | 3099篇 |
口腔科学 | 5068篇 |
临床医学 | 26213篇 |
内科学 | 24701篇 |
皮肤病学 | 3249篇 |
神经病学 | 12730篇 |
特种医学 | 3545篇 |
外科学 | 17789篇 |
综合类 | 156篇 |
一般理论 | 14篇 |
预防医学 | 13733篇 |
眼科学 | 2111篇 |
药学 | 1219篇 |
中国医学 | 18篇 |
肿瘤学 | 8904篇 |
出版年
2023年 | 5010篇 |
2022年 | 1087篇 |
2021年 | 2772篇 |
2020年 | 5358篇 |
2019年 | 2108篇 |
2018年 | 6939篇 |
2017年 | 7351篇 |
2016年 | 7956篇 |
2015年 | 8048篇 |
2014年 | 10473篇 |
2013年 | 12237篇 |
2012年 | 3970篇 |
2011年 | 3700篇 |
2010年 | 6869篇 |
2009年 | 9124篇 |
2008年 | 3596篇 |
2007年 | 2614篇 |
2006年 | 3755篇 |
2005年 | 2308篇 |
2004年 | 1682篇 |
2003年 | 1364篇 |
2002年 | 1245篇 |
2001年 | 1840篇 |
2000年 | 1128篇 |
1999年 | 1674篇 |
1998年 | 2102篇 |
1997年 | 1876篇 |
1996年 | 1978篇 |
1995年 | 1714篇 |
1994年 | 1111篇 |
1993年 | 959篇 |
1992年 | 757篇 |
1991年 | 645篇 |
1990年 | 526篇 |
1989年 | 534篇 |
1988年 | 514篇 |
1987年 | 381篇 |
1986年 | 361篇 |
1985年 | 307篇 |
1984年 | 278篇 |
1983年 | 310篇 |
1982年 | 262篇 |
1981年 | 235篇 |
1980年 | 138篇 |
1979年 | 76篇 |
1978年 | 142篇 |
1977年 | 132篇 |
1976年 | 98篇 |
1974年 | 80篇 |
1972年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Tyler B. Kratzer MPH Ahmedin Jemal DVM PhD Kimberly D. Miller MPH Sarah Nash PhD Charles Wiggins PhD Diana Redwood PhD Robert Smith PhD Rebecca L. Siegel MPH 《CA: a cancer journal for clinicians》2023,73(2):120-146
American Indian and Alaska Native (AIAN) individuals are diverse culturally and geographically but share a high prevalence of chronic illness, largely because of obstacles to high-quality health care. The authors comprehensively examined cancer incidence and mortality among non-Hispanic AIAN individuals, compared with non-Hispanic White individuals for context, using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Overall cancer rates among AIAN individuals were 2% higher than among White individuals for incidence (2014 through 2018, confined to Purchased/Referred Care Delivery Area counties to reduce racial misclassification) but 18% higher for mortality (2015 through 2019). However, disparities varied widely by cancer type and geographic region. For example, breast and prostate cancer mortality rates are 8% and 31% higher, respectively, in AIAN individuals than in White individuals despite lower incidence and the availability of early detection tests for these cancers. The burden among AIAN individuals is highest for infection-related cancers (liver, stomach, and cervix), for kidney cancer, and for colorectal cancer among indigenous Alaskans (91.3 vs. 35.5 cases per 100,000 for White Alaskans), who have the highest rates in the world. Steep increases for early onset colorectal cancer, from 18.8 cases per 100,000 Native Alaskans aged 20–49 years during 1998 through 2002 to 34.8 cases per 100,000 during 2014 through 2018, exacerbated this disparity. Death rates for infection-related cancers (liver, stomach, and cervix), as well as kidney cancer, were approximately two-fold higher among AIAN individuals compared with White individuals. These findings highlight the need for more effective strategies to reduce the prevalence of chronic oncogenic infections and improve access to high-quality cancer screening and treatment for AIAN individuals. Mitigating the disparate burden will require expanded financial support of tribal health care as well as increased collaboration and engagement with this marginalized population. 相似文献
2.
3.
4.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
5.
6.
7.
Alzina Koric MPP Chun-Pin Chang PhD Bayarmaa Mark MS Kerry Rowe PhD John Snyder PhD Mark Dodson MD Vikrant G. Deshmukh PhD Michael G. Newman MS Alison M. Fraser MPH Ken R. Smith PhD Ankita P. Date MS Lisa H. Gren PhD Christina A. Porucznik PhD Benjamin A. Haaland PhD N. Lynn Henry MD Mia Hashibe PhD 《Cancer》2022,128(14):2826-2835
8.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
9.
Simone Oerlemans PhD Fabio Efficace PhD Charalampia Kyriakou PhD MD Ana Carolina Freitas PhD MD Omar Shamieh PhD MD Carien L. Creutzberg PhD MD Jens Lehmann PhD Duska Petranovic PhD MD Eva Nagele PhD Anne Bredart PhD Dong Dong PhD Christian W. Scholz PhD MD Giovanni Caocci PhD MD Stefano Molica PhD MD Laimonas Griskevicius PhD MD Aliki Xochelli PhD MD Jacobien M. Kieffer PhD Joost A. Agelink van Rentergem PhD Waleed Alrjoub BSN Anja Mueller PhD Maria Gomes Da Silva PhD MD Filipa Alves da Costa PhD PharmD Sandra Malak PhD MD Kim Cocks PhD Lonneke V. van de Poll-Franse PhD the EORTC Quality of Life Group 《Cancer》2023,129(17):2727-2740
Background
Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high-grade (HG)- and low-grade (LG)-NHL: the EORTC QLQ-NHL-HG29 and the EORTC QLQ-NHL-LG20 to supplement the core questionnaire (EORTC QLQ-C30).Methods
Overall, 768 patients with HG-NHL (N = 423) and LG-NHL (N = 345) from 12 countries completed the QLQ-C30, QLQ-NHL-HG29/QLQ-NHL-LG20 and a debriefing questionnaire at baseline, and a subset at follow-up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49).Results
Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ-NHL-HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ-NHL-LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG-NHL and 22%–73% of patients with LG-NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without.Discussion
The use of the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision-making.Plain language summary
- The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires.
- These questionnaires measure health-related quality of life.
- The questionnaires are for patients with high-grade or low-grade non-Hodgkin lymphoma.
- They are called the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20.
- The questionnaires are now internationally validated.
- This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire.
- The questionnaires can now be used in clinical trials and practice.
- With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient.